In search of normoglycaemia in diabetes: controlling postprandial glucose

被引:63
作者
Del Prato, S [1 ]
机构
[1] Univ Pisa, Sch Med, Dept Endocrinol & Metab, Sect Diabet, I-56100 Pisa, Italy
关键词
hypoglycaemia; postprandial glucose; postchallenge glucose; glycaemic control; diabetic complications;
D O I
10.1038/sj.ijo.0802172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hyperglycaemia is the diagnostic criterion and a main prognostic parameter in diabetes. Epidemiological and intervention studies have defined the target values for glycaemic control, and there is general consensus that antihyperglycaemic treatment should aim at reducing HbA(1c) levels below 7%. In order to achieve this goal it is important that the entire daily glucose profile is reduced. This can be accomplished only by therapies designed to tackle both basal and postprandial hyperglycaemia. However, an increasing bulk of data suggest that postprandial glucose may be even more deleterious that fasting hyperglycaemia in determining the risk for long-term diabetic complications. A strong association has been recognized for a long time between 2 h post-oral glucose tolerance test (OGTT) glucose levels and mortality and cardiovascular disease. Although these data cannot be directly extrapolated to daily life conditions, excessive glucose excursion after the ingestion of a meal seems to be a common phenomenon even in treated diabetic individuals. Rapid-acting insulin analogues, used as the prandial component insulin replacement therapy and short-acting insulin secretagogues, targeting postprandial glucose control, may have a useful new role to play in the management of diabetes mellitus. These interventions have successfully limited postprandial glycaemic exposure, but evidence is still awaited that these outcomes will translate into prognostic benefits. Other components have to be considered in the search for strict glycaemic control. Diabetic patients with similar HbA(1c) values may differ in term of glucose stability. Data are available that suggest that patients with larger glucose fluctuation within the day and from day-to-day may be exposed to greater risk of diabetic complications. Therefore, in designing strategies to reduce the burden of diabetic complication both a quantitative effect of hyperglycaemia (fasting, postprandial hyperglycaemia, and HbA(1c)) as well as a qualitative component (glucose stability) should be taken into account.
引用
收藏
页码:S9 / S17
页数:9
相关论文
共 73 条
  • [1] American Association of Clinical Endocrinologists, 2000, Endocr Pract, V6, P43
  • [2] American Diabetes Association, 2001, Diabetes Care, V24, P775
  • [3] Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus
    Anderson, JH
    Brunelle, RL
    Keohane, P
    Koivisto, VA
    Trautmann, ME
    Vignati, L
    DiMarchi, R
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) : 1249 - 1255
  • [4] Improved mealtime treatment of diabetes mellitus using an insulin analogue
    Anderson, JH
    Brunelle, RL
    Koivisto, VA
    Trautmann, ME
    Vignati, L
    DiMarchi, R
    Cameron, DP
    Yeu, DK
    Zimmet, P
    Lauvaux, JP
    VanGaal, LF
    Chiasson, JL
    Fettes, IM
    Tan, MH
    Toth, EL
    Charbonnel, B
    Selam, JL
    Haslbeck, M
    SchulzeSchleppinghoff, B
    Karasik, A
    Hazenberg, HJ
    VanDoorn, LG
    Bonnici, FB
    Hough, S
    Mollentze, WF
    Moore, R
    Omar, MA
    Robertson, LI
    VanRooyen, RJ
    DeLeiva, A
    Jara, A
    Vazquez, JA
    Arslanian, S
    Bastyr, EJ
    Bergenstal, RM
    Blonde, L
    Boyce, PA
    Chase, HP
    Clarke, DH
    Davidson, J
    Garber, A
    Goldberg, RB
    Guthrie, RA
    Mayfield, RK
    Mengel, MC
    Prince, MJ
    Reeves, ML
    Rosenzweig, JL
    Schade, DS
    Soeldner, JS
    [J]. CLINICAL THERAPEUTICS, 1997, 19 (01) : 62 - 72
  • [5] [Anonymous], 1999, Diabet Med, V16, P716
  • [6] [Anonymous], 1995, DIABETES, V44, P968
  • [7] Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro
    Assert, R
    Scherk, G
    Bumbure, A
    Pirags, V
    Schatz, H
    Pfeiffer, AFH
    [J]. DIABETOLOGIA, 2001, 44 (02) : 188 - 195
  • [8] Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes
    Avignon, A
    Radauceanu, A
    Monnier, L
    [J]. DIABETES CARE, 1997, 20 (12) : 1822 - 1826
  • [9] High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men -: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study
    Balkau, B
    Shipley, M
    Jarrett, RJ
    Pyörälä, K
    Pyörälä, M
    Forhan, A
    Eschwège, E
    [J]. DIABETES CARE, 1998, 21 (03) : 360 - 367
  • [10] Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
    Bastyr, EJ
    Johnson, ME
    Trautmann, ME
    Anderson, JH
    Vignati, L
    [J]. CLINICAL THERAPEUTICS, 1999, 21 (10) : 1703 - 1714